nach oben

Seminars in Immunopathology

Erschienen in:

01.09.2013 | Review

Tissue macrophage heterogeneity: issues and prospects

verfasst von: Siamon Gordon, Annette Plűddemann

Erschienen in: Seminars in Immunopathology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The vast majority of macrophages in the body are present in tissues outside the circulation, yet their remarkable phenotypic heterogeneity within different anatomical compartments in the steady state and disease remains essentially unexplored. The development of immunocytochemical and fluorescent histological methods has revealed the presence and morphological diversity of macrophages within tissues, especially in the mouse, but functional specialisation in situ is difficult to establish and their mechanistic basis remains unknown, particularly in humans, in spite of the rich material available. In this review, we consider some of the technical issues that hamper investigation, assess the contribution of cell differentiation and modulation to macrophage heterogeneity within tissues and illustrate variation of macrophages and closely related cells in selected organs in mouse and man.

Ginhoux F et al (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330(6005):841–845PubMedCrossRef

Merad M et al (2002) Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3(12):1135–1141PubMedCrossRef

Schulz C et al (2012) A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336(6077):86–90PubMedCrossRef

Yona S et al (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38(1):79–91PubMedCrossRef

Swirski FK et al (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325(5940):612–616PubMedCrossRef

Geissmann F et al (2010) Development of monocytes, macrophages, and dendritic cells. Science 327(5966):656–661PubMedCrossRef

Jenkins SJ et al (2011) Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332(6035):1284–1288PubMedCrossRef

Meredith MM et al (2012) Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady state. J Exp Med 209(9):1583–1593PubMedCrossRef

Satpathy AT et al (2012) Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med 209(6):1135–1152PubMedCrossRef

10.

Kaplan G (2013) Macrophages in tuberculosis: friend or foe. Semin Immunopathol. This Issue

11.

Libby P (2013) Monocyte heterogeneity in cardiovascular disease. Semin Immunopathol. This Issue

12.

Biswas SK, Allavena P, Mantovani A (2013) Tumour-associated macrophages: functional diversity, clinical significance and open questions. Semin Immunopathol. doi:10.1007/s00281-013-0367-7

13.

den Haan JMM, Martinez-Pomares L (2013) Macrophage heterogeneity in lymphoid tissues. Semin Immunopathol. doi:10.1007/s00281-013-0378-4

14.

Perry VH (2013) Microglia in chronic neurodegeneration: the contribution of microglia priming and systemic inflammation. Semin Immunopathol. doi:10.1007/s00281-013-0382-8

15.

Gordon S et al (2011) F4/80 and the related adhesion-GPCRs. Eur J Immunol 41(9):2472–2476PubMedCrossRef

16.

Austyn JM, Gordon S (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11(10):805–815PubMedCrossRef

17.

Hume DA (2013) The macrophage. http://www.macrophages.com/home. Accessed 9 May

18.

Lin HH et al (2005) The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 201(10):1615–1625PubMedCrossRef

19.

Crocker PR, Gordon S (1989) Mouse macrophage hemagglutinin (sheep erythrocyte receptor) with specificity for sialylated glycoconjugates characterized by a monoclonal antibody. J Exp Med 169(4):1333–1346PubMedCrossRef

20.

Taylor PR et al (2005) Macrophage receptors and immune recognition. Annu Rev Immunol 23:901–944PubMedCrossRef

21.

van der Laan LJ et al (1997) Macrophage scavenger receptor MARCO: in vitro and in vivo regulation and involvement in the anti-bacterial host defense. Immunol Lett 57(1–3):203–208PubMedCrossRef

22.

Keshav S et al (1991) Lysozyme is an inducible marker of macrophage activation in murine tissues as demonstrated by in situ hybridization. J Exp Med 174(5):1049–1058PubMedCrossRef

23.

Geissmann F, Jung S, Littman DR (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19(1):71–82PubMedCrossRef

24.

Egen JG et al (2008) Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28(2):271–284PubMedCrossRef

25.

Collin M et al (2013) Monocytes, macrophages, and dendritic cells. In: Wintrobe’s clinical hematology. Lippincott Williams & Wilkins, Philadelphia

26.

Chavele KM et al (2010) Mannose receptor interacts with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice. J Clin Invest 120(5):1469–1478PubMedCrossRef

27.

Cohen NR et al (2013) Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells. Nat Immunol 14(1):90–99PubMedCrossRef

28.

Miller JC et al (2012) Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol 13(9):888–899PubMedCrossRef

29.

Martinez FO et al (2013) Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 121(9):e57–e69PubMedCrossRef

30.

Kohyama M et al (2009) Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 457(7227):318–321PubMedCrossRef

31.

Perez OD, Nolan GP (2006) Phospho-proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single-cell level. Immunol Rev 210:208–228PubMedCrossRef

32.

Panicker LM et al (2012) Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A

33.

Gerner MY et al (2012) Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity 37(2):364–376PubMedCrossRef

Titel: Tissue macrophage heterogeneity: issues and prospects
verfasst von: Siamon Gordon
Annette Plűddemann
Publikationsdatum: 01.09.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Seminars in Immunopathology / Ausgabe 5/2013
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-013-0386-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Monocyte heterogeneity in cardiovascular disease

Tumor-associated macrophages: functional diversity, clinical significance, and open questions

Macrophages in tuberculosis: friend or foe

Macrophage heterogeneity in lymphoid tissues